Please login to the form below

Not currently logged in
Email:
Password:

Drug prices

This page shows the latest Drug prices news and features for those working in and with pharma, biotech and healthcare.

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013. Drug makers and pharmacy benefit managers continued to point fingers over the blame for escalating prices of insulin in the US at a ... why list prices are so high, given that the average price of

Latest news

  • Tit for tat as PBMs blame pharma for high drug prices Tit for tat as PBMs blame pharma for high drug prices

    The pharma executives directed the blame for high drug prices squarely at the PBMs during their time in the spotlight, claiming that discounts and rebates were not being handed on to ... supply chain as they negotiate drug prices for health plans – are

  • Brexit causing ‘significant’ generic drug shortages Brexit causing ‘significant’ generic drug shortages

    Pharmacy contractors will then get automatically reimbursed on the basis of the concessionary prices, instead of the drug tariff list price. ... The list was first introduced back in 2014 to avoid a chain of problems for the NHS associated with higher

  • Biogen’s Spinraza overpriced, says ICER Biogen’s Spinraza overpriced, says ICER

    The drug is a key growth driver for the drug maker, earning around $1.7bn in sales last year. ... The medicines cost debate in the US is one that has been front and centre since Trump declared war on prescription drug prices last year.

  • Gottlieb signs off with flair – and pledge of further drug price commentary Gottlieb signs off with flair – and pledge of further drug price commentary

    These remarks add to commentary Gottlieb made on the wider question of competition and drug prices last week at a Alliance for a Stronger FDA meeting last week. ... Talking in a‘fireside chat’ with former FDA commissioner Mark McClellan, Gottlieb

  • Trump budget targets rebates, out-of-pocket costs Trump budget targets rebates, out-of-pocket costs

    The budget proposes removing the cap on Medicaid manufacturer drug rebates “to ensure rebates reflect all price increases for a drug,” and would also prevent manufacturers from using authorised generics to ... The budget would fundamentally upset the

More from news
Approximately 18 fully matching, plus 159 partially matching documents found.

Latest Intelligence

  • The Orkambi blame game The Orkambi blame game

    Grilling by MPs sheds some light on long-running row over CF drug. " />. ... The three-hour evidence session also bore some resemblance to the recent interrogation of seven big pharma CEOs by a US Senate committee enquiry into US drug prices, albeit with

  • #OrkambiNow? #OrkambiNow?

    died from the disease who might have lived had they received the drug. ... Not only that, making the offer public broke the longstanding golden rule of confidentiality which allows drug companies to cut prices in one country without exposing them to

  • Comment: the new UK pricing deal – welcome news, but lessons to be learned Comment: the new UK pricing deal – welcome news, but lessons to be learned

    There is no conceivable scenario in which any government would accept the political risk of reducing the threshold: every patient denied access to a drug as a result would be a ... I do not believe the Government wants to be trapped in a situation where

  • Deal Watch October 2018

    US drug prices. In other news from the US, there are now expectations of a legislative stalemate following the mid‐term elections in early November. ... It is worth remembering that there are still a few areas where both political parties are prepared

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Trump had tweeted days before that Pfizer “should be ashamed that they have raised drug prices for no reason”, claiming they were “taking advantage of the poor and others unable to ... The Trump administration has also just floated the idea of

More from intelligence
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Part 1: Segmentation and comparator choice - lessons for cancer drug market access in Germany. ... How to prepare. Germany is one of the largest pharmaceutical markets in Europe and drug prices there are used as reference prices in other markets.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics